Crossmark

A retrospective cohort analysis comparing the effectiveness and safety of perioperative angiotensin II to adrenergic vasopressors as a first-line vasopressor in kidney transplant recipients

Crossref DOI link: https://doi.org/10.1186/s44158-024-00207-w

Published Online: 2024-10-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Urias, George

Benken, Jamie

Nishioka, Hokuto

Benedetti, Enrico

Benken, Scott T.
License Information

Text and Data Mining valid from 2024-10-17

Version of Record valid from 2024-10-17
More Information

Article History

Received: 20 August 2024

Accepted: 8 October 2024

First Online: 17 October 2024

Declarations

:

: A waiver of informed consent was granted by the Office for the Protection of Research Subjects at the University of Illinois Chicago for this research study.

: SB serves on the speaker's bureau for Innoviva, the manufacturer of synthetic angiotensin II (Giapreza).

Document is current

Any future updates will be listed below